The present invention includes a method of treating prostate cancer in a human subject in need thereof, comprising administering to the subject an effective amount of a composition comprising interleukin-2 (IL2), and administering to the subject a cell expressing a chimeric antigen receptor (CAR) which specifically binds prostate specific membrane antigen (PSMA), thereby treating prostate cancer in the human subject in need thereof.
